On Jul. 22, 20120, Evotec announced that the U.S. Department of Defense (DoD) had awarded its Seattle-based subsidiary, Just – Evotec Biologics, a contract valued up to $ 18.2 million to develop and manufacture monoclonal antibodies (‘mAbs’) for treatment and/or prevention of COVID-19. The goal of this programme was to rapidly and efficiently deliver the mAbs to the DOD.

Under the contract, Just – Evotec Biologics will design a highly efficient manufacturing process for the production of Current Good Manufacturing Practice (“cGMP”) clinical supplies of two monoclonal antibodies directed against SARS-CoV-2 antigens.